Advertisement
The Chinese Federation hailed Goodnak(R) as a breakthrough Chinesemedical/beauty product at a gala ceremony in Shenzhen, China, where the awardwas presented to Jade executives, who said it is set to become one of thepremiere beauty products in China.
Advertisement
Goodnak(R) is a high quality injectable anti-aging & skin care productthat contains an amalgam of various therapeutic elements including humanplacental histosolution (HPH). Jade has begun selling Goodnak(R) throughwholesale distribution channels that service high-end beauty salon and plasticsurgery hospitals and medical cosmetology institutions. Goodnak productinformation is available on Jade Pharma's product specific website:http://www.jade-amdl.com.
Gary Dreher, CEO of AMDL, noted that AMDL is now a health care company,with noteworthy pharmaceutical products for treating disease, a diagnosticcompany, with a test to detect cancer at early stages, and a nutraceuticalCompany, with significant products for wellness. "We are confident thatGoodnak(R) will become a large part of our success both short and longterm,"Mr. Dreher said.
About AMDL: More information about AMDL and its products can be obtainedat http://www.amdl.com.
About Jade: Jade has access to the fastest growing pharmaceutical andconsumer market in the world: China. AMDL, through its Jade subsidiaries,currently holds licenses for 133 products that are manufactured as largevolume injection fluids, tablets and other related products. It currentlymanufactures over 20 key generic, over the counter and supplementalpharmaceutical products under certified Chinese Good Manufacturing Practice(CGMP) standards.
Forward-Looking Statements: This news release contains forward-lookingstatements within the meaning of the Private Securities Litigation Reform Actof 1995. Such statements are subject to certain risks and uncertainties, andactual circumstances, events or results may differ materially from thoseprojected in such forward-looking statements. The Company cautions readers notto place undue reliance on any forward-looking statements. The Company doesnot undertake, and specifically disclaims any obligation, to update or revisesuch statements to reflect new circumstances or unanticipated events as theyoccur.Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 Voice Mail: 714.505.4460
SOURCE AMDL, Inc.
